Ceritinib shows good activity against tumors with ALK rearrangements
Image: PD 1. There was a 58% response rate to ceritinib among non-small-cell lung cancer (NSCLC) patients. 2. Median progression-free ...
Image: PD 1. There was a 58% response rate to ceritinib among non-small-cell lung cancer (NSCLC) patients. 2. Median progression-free ...
Image: PD 1. Pleural effusions were associated with worse survival in non-small-cell lung cancer (NSCLC), particularly when they arose in ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.